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Aim: To determine the quantitative gene expression of KRAS codon 12 mutant, TACSTD2, Ku70 and SERIN1 in samples of tumor 
tissue and to relate them with clinical-pathological characteristics of colorectal cancer. Methods: Samples of tumor and normal tis-
sue of patients surgically treated for colorectal cancer between July 2005 and July 2009 were stored in a tissue bank. These samples 
were studied with the technique of real-time polymerase chain reaction in respect to expression of the following genes: KRAS codon 
12 mutation, TACSTD2, Ku70, and SERIN1. Results: Tumor samples of 37 patients were studied. The mean age was 65.5 years. 
Twenty one patients (56.8%) were male. Nine patients (24.3%) were classified as TNM stage I, 11 patients (29.8%) as TNM stage II, 
eight patients (21.6%) as TNM stage III and nine patients (24.3%) as TNM stage IV. The Ku70 expression in poorly-differentiated 
tumors is significantly higher than in well and moderately-differentiated tumors (2.76 vs. 1.13; p < 0.05). SERIN1, TACSTD2 and 
KRAS codon 12 mutation are not associated with clinical-pathological characteristics of colorectal cancer. Conclusion: Ku70 expres-
sion in poorly-differentiated tumors is significantly higher than in well and moderately-differentiated colorectal tumors.
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Genetic disorders play a key role in the colorectal 
carcinogenesis, either in its initiation or its progression 
[1]. During the last years experts in colorectal cancer 
(CRC) have focused its attention mainly over the KRAS 
gene. KRAS mutations are observed in around 40% 
of CRC [2–5]. About 90% of these mutations occur in the 
codons 12 (70–80%) and 13 (20–30%) [2, 6, 7]. It has 
been demonstrated that mutations on codon 12 are as-
sociated with a poorer prognosis of CRC [3]. For this 
reason, many authors currently are looking for new genes 
potentially associated to the clinical-pathological fea-
tures and the prognosis of patients with CRC. 
The tumor-associated calcium signal transducer 
(TACSTD2), also known as TROP2, is located on chro-
mosome 1 (1p32–1p31) [5]. TACSTD2 overexpression 
has been observed in most human carcinomas and 
proposed as a possible stimulus for growth and tumor 
development [8–14]. Its overexpression has been as-
sociated with decreased overall survival, increased rate 
of CRC-related-death, and higher risk of liver metastasis 
[8, 15, 16]. The Ku70 protein is a homonymous polypep-
tide of 70 kDa. It is an antiapoptotic protein that plays 
an essential role in the repair of DNA double strand break 
damage induced by ionizing radiation in mammalian cells 
[17–19]. It was demonstrated that Ku70 expression is as-
sociated with decreased disease-free-survival in CRC 
and with impaired response to radiotherapy in rectal can-
cer patients [20–21]. The SERIN1 expression, not widely 
studied yet, seems also related to the prognosis of CRC 
patients, specifically with the overall survival at 36 months 
[22]. The aim of this study is to evaluate the association 
between KRAS codon 12 mutation, TACSTD2, Ku70 and 
SERIN1 expression, and clinical-pathological characte-
ristics with prognostic relevance.
MATERIALS AND METHODS
Population and samples. This is a cross-sectional 
study which enrolled patients with CRC who were 
surgically treated at the Division of Colorectal Surgery 
of Hospital São Lucas, Pontificia Catholic University 
of Rio Grande do Sul, between July 2005 and July 
2009. Samples of 1 cm2 were taken from the center 
of the resected tumor, immediately frozen in liquid 
nitrogen, and subsequently stored in a tissue bank 
at — 80 °C as described previously [23–25]. Patients 
who underwent neoadjuvant radiochemotherapy, with 
familial adenomatous polyposis, hereditary nonpol-
yposis CRC, inflammatory bowel disease, synchronic 
or previous CRCs, any synchronic or previous cancer, 
incomplete data or with no expression of the positive 
control gene (β2-microglobulin) were excluded. All pa-
tients signed an informed consent form for the collec-
tion, storage and studying of their samples. The study 
protocol was approved by the local ethics committee. 
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Clinical staging and pathological examination. 
Preoperative oncological workup included colonoscopy, 
computerized tomography and/or ultrasonography 
of the abdomen, and chest radiography and/or com-
puterized tomography. Right and left-sided cancers 
were defined as cancer located respectively proximal 
and distal to the splenic flexure. Rectal cancer was 
defined as that situated under the sacral promontory. 
Pathological examinations were performed by the same 
pathologist according to the International Classification 
of Diseases for Oncology. Gene expression was com-
pared to the following clinical-pathological features: 
age, gender, race, preoperative measurement of the 
carcinoembryonic antigen (CEA), tumor location, TNM 
classification, American Joint Committee on Cancer 
(AJCC) stage, liver and lung metastasis, tumor grade, 
vascular invasion, and mucus production  [26].
Technique of molecular analysis. The RNA extrac-
tions were performed with Trizol (Trizol® Reagent, Invi-
trogen, USA) from a sample of 100 mg of tumor tissue, 
according to the manufacturer’s instructions. The quantity 
and quality of RNA were determined with spectropho-
tometry (Gene Quant®, Pharmacia Biotech, USA), from 
duplicate aliquots of 1 ml of solution. The synthesis 
of complementary DNA (cDNA) was performed from 
2 mg of the total RNA through polymerase chain reaction 
(PCR) with reverse transcription (SuperScript First-Strand 
Synthesis System®, Invitrogen, USA). The real-time PCRs 
were performed with the DNA Engine Opticon 2 Real-Time 
PCR System® (Bio-Rad, USA). The final volume per reac-
tion was 25 μl, containing 2 μl of cDNA diluted 10 times, 
0.1 μM of primer sense and antisense, 12.5 μl of Platinun-
SybrGreen qPCR Supermix-UDG® and ultrapure water 
q.s.p. β2-microglobulin served as a positive control in each 
experiment, while PCR reagents without template were run 
in parallel as no template controls. The conditions of the 
reactions were: 94 °C (2 min), 94 °C (50 s), X °C (45 s), 
72 °C (45 s), followed by 45 cycles with a final extension 
of 2 min at 72 °C and melting curve of 56 to 96 °C (increas-
ing by 0.5 °C each 10 s). Primers sequences were TAC-
STD2 (sense: TGACCTCCAAGTGTCTGCTG/ antisense: 
GTCGTAGAGGCCATCGTTGT), Ku70 (sense: CCACAG-
GAAGAAGAGTTGGA / antisense: CTGCTCTGGAGTTGC-
CATGA), SERIN1 (sense: TGATGGATCACTGGAGGATG / 
antisense: AGCATGAAGTGAAAGAAGGA) and KRAS 
codon 12 (sense: GACTGAATATAAACTTGTGG / antisense: 
CCAGGTCCTGGTAAGAAACT). The annealing tempera-
ture was 57 °C for all genes, except for SERIN1 (54 °C). 
Statistical analysis. The SPSS® software, version 
15.0, was used for statistical analysis. Mann — Whitney 
and the Kruskal — Wallis tests were used to compare 
categorical and quantitative variables, respectively. Pear-
son’s correlation coefficient was used to compare non-
parametric quantitative variables. The p values < 0.05 were 
considered to indicate statistical significance. 
RESULTS AND DISCUSSION
In molecular study samples from 37 patients were 
analyzed. The exclusion criterion adopted aimed to select 
a homogeneous sample, composed exclusively of sub-
jects with sporadic CRC. Once it is known that the chemo-
radiotherapy reduces the amount of tumor cells and 
interferes in the performance of the PCR assay, we de-
cided to exclude patients who underwent preoperative 
chemoradiotherapy. That is the reason why the sample 
studied showed fewer rectal tumors (18.9%) than usually 
described in other publications [6]. The sample fixation 
in formalin can chemically modified the DNA structure 
and interfere in the reaction efficiency. For this reason, 
we used fresh frozen samples instead of formalin-fixed 
paraffin-embedded tumor samples [27]. Patients’ 
demographic and clinical data and tumor pathological 
features are summarized in Table 1. Two patients (5.4%) 
had peritoneal implants diagnosed during the surgery, 
while one patient (2.7%) had lung metastasis discovered 
during the clinical staging.
Table 1. Clinical-pathological characteristics
N = 37 (%)
Gender
•	Male
•	Female
21(56.8)
16 (43.2)
Age (years) a 65.5 (12.1)
Race
•	Caucasian
•	African-American
•	Asian
34 (91.9)
1 (2.7)
2 (5.4)
Preoperative CEA (ng/mL) b 2.5 (1.0; 5.4)
Tumor location
•	Right colon
•	Left colon
•	Rectum
12 (32.4)
18 (48.7)
7 (18.9)
Category T (TNM)
•	T1
•	T2
•	T3
•	T4
7 (18.9)
2 (5.4)
27 (73.0)
1 (2.7)
Category N (TNM)
•	N0
•	N1
•	N2
20 (54.1)
13 (35.1)
4 (10.8)
Category M (TNM)
•	M0
•	M1
9 (24.4)
28 (75.6)
Liver metastasis 
•	Absence
•	Presence
31 (83.6)
6 (16.2)
AJCC stage
•	I
•	II
•	III
•	IV
7 (24.3)
11 (29.8)
8 (21.6)
9 (24.3)
Tumor grade
•	G1 or G2
•	G3
35 (94.6)
2 (5.4)
Vascular invasion
•	Presence
•	Absence
7 (18.9)
30 (81.1)
Mucus production
•	Presence
•	Absence
5 (13.5)
32 (86.5)
Note: G1:  well-differentiated; G2: moderately-differentiated; G3: poorly-dif-
ferentiated; amean (standard deviation) value expressed; bmedian (25% and 
75% quartile) value expressed.
Male patients with CRC showed a higher  TACSTD2 and 
SERIN1 expression than women (TACSTD2 = 2.04 vs. 
0.56, p = 0.381; and SERIN1 = 1.79 vs. 1.59, p = 0.415). 
This tendency is opposite to that observed in respect 
to Ku70 expression (male: 1.02 vs. female: 1.18, p = 
0.307) and KRAS codon 12 mutation (male: 0.42 vs. 
30 Experimental Oncology 33, 28–32, 2011 (March)
female: 0.48, p = 0.817). Despite these facts the associa-
tions between gene expressions and gender were not 
statistically significant. TACSTD2, SERIN1 and KRAS co-
don 12 mutation expressions were inversely proportional 
to patient’s age (rs = – 0.217, rs = – 0.193 and rs = – 0.146, 
respectively) and were also not statistically significant 
(p = 0.332, p = 0.306 and p = 0.460 respectively).
The Ku70 quantitative expression was directly pro-
portional to patient’s age, but with a low grade of cor-
relation (rs = 0.041), and no statistical significance 
(p = 0.824). Fig. illustrates Ku70 real-time PCR results.
Distal tumors presented higher expression 
of TACSTD2 (rectum = 4.99 vs. left colon = 1.67 vs. 
right colon = 0.57, p = 0.236), while proximal tumors 
tend to present higher expression of Ku70 (right colon 
= 1.85 vs. left colon = 1.13 vs. rectum = 0.78, p = 0.413). 
SERIN1 and KRAS codon 12 mutation did not show 
a pattern of quantitative gene expression according 
to tumor localization (right colon = 1.88 and 0.48 vs. left 
colon = 2.78 and 0.22 vs. rectum = 2.00 and 0.69, p = 
0.747 and 0.337, respectively). Gene expressions and 
CEA preoperative measurement showed low correlation 
and no statistically significant association. Data regard-
ing the correlation between gene expression and quan-
titative variables, age and CEA, are shown in Table 2.
Table 2. Correlation between quantitative variables and gene expressions
TACSTD2 KU70 SERIN1 KRAS codon 12
rs p rs p rs p rs p
Age -0.217 0.332 0.041 0.824 -0.193 0.306 -0.146 0.460
CEA 0.088 0.729 -0.108 0.607 0.210 0.337 -0.351 0.118
TACSTD2 and Ku70 quantitative expression were 
lower in tumors with vascular invasion on histopathol-
ogy examination (0.04 vs. 0.95, p = 0.557; and 0.72 vs. 
1.18; p = 0.381, respectively). This finding is contrary 
to that observed in respect to SERIN1 (4.90 vs. 1.37, p 
= 0.649) and KRAS codon 12 mutation (0.48 vs. 0.42, 
p = 0.874) expressions. The Ku70 expression in poorly-
differentiated tumors is statistically higher than in well 
and moderately-differentiated tumors (2.76 vs. 1.13, 
p = 0.030). No association was observed between 
tumor grade and TACSTD2, SERIN1 and KRAS codon 
12 mutation. Lower quantitative expression of all genes 
was observed among tumors with intra or extra-cellular 
mucus production (TACSTD2 = 0.33 vs. 0.95, p = 0.312; 
Ku70 = 0.90 vs. 1.17, p = 0.392; SERIN1 = 1.29 vs. 
1.92, p = 0,839): KRAS codon 12 mutation = 0.33 vs. 
0.45, p = 0.762).
With regard to category T, tumors with deep-
er invasion of the colorectal wall revealed higher 
TACSTD2 expression (T1 = 0.48 vs. T2 = 1.16 vs. T3 = 
2.47, p = 0.409). KU70, SERIN1 and mutant KRAS did 
not show any expression trend. The only patient with 
T4 tumor was excluded from the analysis. TACSTD2, 
Ku70 and SERIN1 quantitative expression showed 
no statistically significant association with category 
N (TACSTD2: N0 = 0.79 vs. N1 = 4.21 vs. N2 = 0.22, 
 p = 0.536; Ku70: N0 = 1.18 vs. N1 = 0.86 vs. N2 = 1.36, 
p  = 0.567; SERIN1: N0 = 2.03 vs. N1 = 1.45 vs. N2 = 0.46, 
p = 0.606; KRAS codon 12 mutation: N0 = 0.45 vs. N1 = 
1.32 vs. N2 = 0.01, p = 0.254). Data concerning the oc-
currence of systemic metastasis (category M) and TNM 
staging were not statistically associated with TACSTD2, 
Ku70 and SERIN1 expressions, and are presented in table 
3. Patients with liver metastasis presented higher gene 
expression levels (TACSTD2 = 8.45 vs. 0.63, p = 0.693; 
Ku70 = 1.89 vs. 1.13, p = 0.256; SERIN1 = 1.88 vs. 1.69, 
p = 0.219). The exception was mutant KRAS (0.02 vs. 
0.54, p = 0.264). These data and the analysis of all the 
other categorical variables are represented in Table 3.
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Figure. Ku70 real-time PCR: a, melting curve; b, amplification curve; c, linear regression of the results
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Despite the great interesting of the international 
scientific community and the numerous publications 
about KRAS gene, testing for KRAS mutations still cur-
rently not standardized [6]. It is known however that 
real-time PCR is the test with the greatest sensitivity 
(96.5%) to detect KRAS mutations [28]. In agreement 
with Cejas et al. [29], we did not observed association 
between mutation in codon 12 and the clinical-path-
ological variables studied. Chang et al. [30] analyzed 
228 cases of CRC with a multiplex PCR and did not 
report association between mutation in codon 12 and 
any clinical-pathological feature other than lymph 
nodes metastasis (p = 0.048). This finding however 
was not confirmed in our study. 
TACSTD2, also known as TROP2, codifies a protein 
that promotes anchorage-independent growth and 
tumorigenesis [31, 32]. TROP2 overexpression occurs 
mainly in rectal cancer and is associated with disease 
recurrence and increased cancer-related-deaths [9, 
16]. Our findings support Ohmachi et al. [9], once both 
studies did not identify association between TROP2 ex-
pression in tumor tissue and age, gender, tumor site, 
histological grade, vascular invasion and lymph node 
metastasis. Unlike this author, we did not observe as-
sociation between TROP2 expression and the occur-
rence of liver metastasis [9]. Our study analyzed tumors 
of the colon and rectum together and like Fang et al. [16] 
we did not identify association between the TROP2 ex-
pression and the occurrence of liver metastasis.
Preoperative radiotherapy reduces the rate of local 
recurrence and improves the chance of survival in pa-
tients with resectable, advanced rectal cancer. Target-
ing the Ku70 and/or Ku80 could inhibit repair of the 
radiation-induced DNA double strand break damage, 
enhancing the radiation response of tumor cells [20, 
21]. Our study was the first to describe the association 
between higher Ku70 expression and low-differentiated 
(tumor grade G3) colorectal cancer (p = 0.03). An im-
munohistochemistry study of CRC patients, performed 
by Komuro et al. [20, 21], did not demonstrate associa-
tion between the Ku70 expression and clinical-patho-
logical features, except the depth of tumor invasion. The 
explanation for this difference may be: (1) limitations 
of the real-time PCR and immunohistochemistry assay; 
(2) discrepancy between gene and protein expressions; 
or (3) compensatory gene expression in the homolo-
gous recombination pathway [21, 33].
The first citation in literature about SERIN1 derives 
from the publication of Eschrich et al. [22]. Using the 
technique of cDNA microarray, this author estab-
lished a panel of 43 genes, including SERIN1, asso-
ciated with an unfavorable prognosis of patients with 
CRC [22]. We did not observe association between 
 SERIN1 expression and clinical-pathological charac-
teristics of CRC. Until the current date our report is the 
unique study concerning this topic.
Some potential limitations of our study require 
further discussion. First, the small number of patients 
Table 3. Relation between categorical variables and TACSTD2, Ku70, SERIN1 and KRAS codon12 mutation expressions
TACSTD2 KU70 SERIN1 KRAS codon 12
Gender 
•	Male
•	Female
2.04 (0.37–8.99)
0.56 (0.17–4.71)
1.02 (0.70–1.55)
1.18 (1.03–26.47)
1.79 (0.68–6.87)
1.59 (0.40–3.70)
0.42 (0.04–1.82)
0.48 (0.02–2.98)
Tumor site b
•	Right colon
•	Left colon
•	Rectum
0.57 (0.08–0.71) 
1.67 (0.07–13.46)
4.99 (4.21–5.77)
1.85 (0.72–2.26)
1.13 (0.74–1.25)
0.78 (0.23–1.71)
1.88 (0.74–2.12)
2.78 (1.08–8.81)
2.00 (0.62–4.24)
0.48 (0.22–1.92)
0.22 (0.02–2.40)
0.69 (0.02–8.17)
Vascular invasion a
•	Presence
•	Absence
0.04 (0.03–10.0)
0.95 (0.41–5.77)
0.72 (0.22–2.99)
1.18 (0.82–1.75)
4.90 (0.26–8.27)
1.37 (0.51–5.87)
0.48 (0.04–1.95)
0.42 (0.01–2.98)
Tumor grade a
•	G1 or G2
•	G3
1.31 (0.25–6.59)
0.59 (0.59–0.59)
1.13 (0.71–1.59)
2.76 (1.19–4.33)(c)
1.45 (0.49–5.87)
1.17 (0.46–1.88) 
0.38 (0.02–1.82)
10.0 (1.90–18.12)
Mucus production
•	Presence
•	Absence
0.33 (0.04–0.63)
0.95 (0.29–6.31)
0.90 (0.33–1.64)
1.17 (0.49–2.66)
1.29 (0.57–7.54)
1.92 (0.91–4.44)
0.33 (0.06–0.61)
0.45 (0.02–1.94)
Category T (TNM) d
•	T1
•	T2
•	T3
0.48 (0.24–1.11)
1.16 (1.10–2.42)
2.47 (0.31–10.92)
1.17 (0.93–1.51)
1.71 (1.21–2.21)
1.11 (0.72–1.85)
1.93 (1.09–4.23)
15.38 (0.73–30.0)
1.45 (0.47–5.26)
1.94 (0.09–2.84)
0.20 (0.02–0.38)
0.45 (0.05–2.17)
Category N (TNM) b
•	N0
•	N1
•	N2
0.79 (0.43–3.60)
4.21 (0.19–14.89)
0.22 (0.22  – 0.22)
1.18 (0.91–2.12)
0.86 (0.34–1.53)
1.36 (0.66–2.62)
2.03 (0.54–5.46)
1.45 (0.58–6.71)
0.46 (0.32–3.94)
0.45 (0.09–1.96)
1.32 (0.03–2.44)
0.01 (0.01–18.13)
Category M (TNM) a
•	M0
•	M1
2.05 (0.49–6.59)
0.34 (0.13–8.46)
1.18 (0.77–1.94)
0.92 (0.59–2.26)
1.69 (0.56–4.96)
1.88 (0.46–6.71)
0.43 (0.04–1.95)
1.68 (0.01–2.98)
Liver metastasis
•	Yes
•	No
8.45 (0.58–16.32)
0.63 (0.08–4.99)
1.89 (0.72–3.99)
1.13 (0.40–1.85) 
1.88 (1.00–3.93)
1.69 (0.67–4.33)
0.06 (0.01–1.89)
0.54 (0.12–1.96)
AJCC stage b
•	I
•	II
•	III
•	IV
0.48 (0.10–1.68)
3.99 (0.79–8.47)
9.62 (4.60–2.94)
0.34 (0.13–8.46)
1.20 (1.17–1.98)
1.15 (0.75–2.31)
0.98  (0.15–1.89)
0.92 (0.59–2.26)
1.93 (0.91–7.04)
2.13 (0.37–5.87)
1.37 (0.56–6.74)
1.88 (0.46–6.71)
1.16 (0.06–2.40)
0.42 (0.09–0.61)
0.05 (0.01–3.08)
1.68 (0.01–2.98)
Note: Gene expression presented through median and inter–quartile range (IQR1; IQR3); aMann — Whitney test; bKruskal–Wallis test; cp < 0.05; done pa-
tient excluded.
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studied difficults the identification of any eventually 
statistically significant difference. Another limitation 
is that we investigate only one type of KRAS mutation, 
precluding us from generalizing our conclusions about 
other mutations of this gene. Finally, we analyzed colon 
and rectal tumors together, making difficult to compare 
our findings with those reported by some other authors.
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